Identification of antipsychotic drug fluspirilene as a potential p53-MDM2 inhibitor: a combined computational and experimental study

Prospective virtual screening for novel p53–MDM2 inhibitors using ultrafast shape recognition

(2014) Sachin P. Patil et al.   JOURNAL OF COMPUTER-AIDED MOLECULAR DESIGN

Transient Protein States in Designing Inhibitors of the MDM2-p53 Interaction

(2013) Michal Bista et al.   STRUCTURE

Global Proteome Analysis of the NCI-60 Cell Line Panel

(2013) Amin Moghaddas Gholami et al.   Cell Reports

Identification of FDA-approved Drugs that Computationally Bind to MDM2

(2012) Wayne A. Warner et al.   Chemical Biology & Drug Design

The Structure-Based Design of Mdm2/Mdmx-p53 Inhibitors Gets Serious

(2011) Grzegorz M. Popowicz et al.   ANGEWANDTE CHEMIE-INTERNATIONAL EDITION

Peptide Activators of the p53 Tumor Suppressor

(2011) Changyou Zhan et al.   CURRENT PHARMACEUTICAL DESIGN

Structural determinants of benzodiazepinedione/peptide-based p53-HDM2 inhibitors using 3D-QSAR, docking and molecular dynamics

(2011) Fangfang Wang et al.   JOURNAL OF MOLECULAR MODELING

Structures of low molecular weight inhibitors bound to MDMX and MDM2 reveal new approaches for p53-MDMX/MDM2 antagonist drug discovery

(2010) Grzegorz M. Popowicz et al.   CELL CYCLE

Cytotoxic effects of antipsychotic drugs implicate cholesterol homeostasis as a novel chemotherapeutic target

(2009) Erik D. Wiklund et al.   INTERNATIONAL JOURNAL OF CANCER

AutoDock4 and AutoDockTools4: Automated docking with selective receptor flexibility

(2009) Garrett M. Morris et al.   JOURNAL OF COMPUTATIONAL CHEMISTRY

Temporal activation of p53 by a specific MDM2 inhibitor is selectively toxic to tumors and leads to complete tumor growth inhibition

(2008) S. Shangary et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA